PEN vs TAK
Penumbra, Inc. vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
PEN
Penumbra, Inc.
67
Buy
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | PEN | TAK |
|---|
| AI Score |
67
|
67
|
| Price |
$326.07
|
$17.49
|
| P/E Ratio |
79.78×
|
48.87×
|
| ROE |
12.4%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.8%
|
62.1%
|
| Debt / Equity |
0.14×
|
0.65×
|
| Dividend Yield |
0.0%
|
3.6%
|
| RSI (14) |
79.6
|
61.6
|
| Beta |
0.701
|
0.088
|
| Expected Upside |
+6.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for PEN versus TAK.
The committee scores are tied.
PEN and TAK both score 67/100.
PEN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 consecutive earnings misses -- execution concerns. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- 2 consecutive earnings misses -- execution concerns — Growth
- RSI at 80 is in overbought territory — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical